Daniel Cho covers the business and financial dimensions of biotechnology and healthcare, with an emphasis on how investment trends reflect deeper shifts in innovation and risk. His reporting explores capital allocation, strategic deals, and market signals across the life sciences. At The Catalyst Brief, Daniel connects financial activity to scientific progress and policy developments to provide a more complete view of the industry.
148 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Regulatory & PolicyAs digital device use becomes ubiquitous in childhood, concerns have risen regarding its impact on development and well-being. The Surgeon General’s advisory highlights the emerging evidence on how excessive or improper screen time can pose real harm, inviting a coordinated response to protect pediatric populations.
Daniel ChoMay 20, 2026
Regulatory & PolicyRecent changes in FDA leadership, marked by the swift departure of Katherine Szarama from CBER’s helm, highlight underlying tensions and ongoing reforms in regulatory oversight of biologics. This article analyzes the context, potential impacts on biopharma innovation, and public trust.
Daniel ChoMay 18, 2026
Biotech InnovationDuracyte's innovative technology leverages engineered cells implanted in patients to produce biologic drugs directly, circumventing traditional manufacturing complexities and enabling real-time control by clinicians. This fusion of biotechnology and electronics heralds a potential shift in drug production and delivery paradigms.
Daniel ChoMay 18, 2026
Biotech InnovationThe FDA has granted approval to BeOne Therapeutics for Beqalzi, its novel therapy for mantle cell lymphoma patients who have experienced relapse or refractory disease. This approval introduces a new class of targeted therapy and represents an important milestone in blood cancer treatment modalities.
Daniel ChoMay 14, 2026
Regulatory & PolicyThe FDA has experienced considerable turnover at its highest leadership levels, including the pending departure of Commissioner Marty Makary and the recent exit of biologics chief Vinay Prasad. These changes could influence regulatory approaches and drug approval processes in the biopharma sector.
Daniel ChoMay 11, 2026
Healthcare InvestmentThe healthcare industry is facing significant financial challenges as bankruptcy filings increase, marking a critical turning point for outpatient and senior care sectors. This post examines the underlying causes, recent market trends including hospital merger and acquisition activity, and potential paths forward for stakeholders.
Daniel ChoMay 8, 2026
Biotech InnovationThe development represents a significant step in combining RNA-based therapeutics with a multi-faceted approach to treating complex liver diseases. Madrigal’s strategy to integrate multiple genetic medicines could transform treatment paradigms for MASH and other metabolic liver disorders, underscoring innovation at the intersection of biotechnology and precision medicine.
Daniel ChoMay 5, 2026
Biopharmaceutical IndustryThe integration of functional medicine into mainstream health insurance networks marks a pivotal shift in healthcare, potentially enhancing patient access and acceptance of holistic treatment models. Parsley Health’s recent agreements with several major insurance companies highlight this transformative trend, opening new avenues for treating chronic and complex conditions.
Daniel ChoMay 5, 2026
Biopharmaceutical IndustryIn a strategic move to strengthen its position in autoimmune and immunology therapeutics, UCB has finalized the acquisition of Candid Therapeutics for $2.2 billion. The deal includes two clinical-stage T cell engagers aimed at resetting the immune system in autoimmune disorders. This acquisition reflects ongoing consolidation trends in pharma and highlights the increasing focus on innovative immune-targeted therapies.
Daniel ChoMay 4, 2026
Biopharmaceutical IndustryThis strategic expansion underlines Novartis’s commitment to solidifying its manufacturing footprint in the US and leveraging the North Carolina biotech cluster. The API plant equips the company with end-to-end production capacity critical for future pharmaceutical innovation and supply chain resilience.
Daniel ChoMay 1, 2026
Regulatory & PolicyRecent regulatory updates include the FDA's new stance on obesity treatment compounding, spotlighting broader policy implications on drug accessibility. Meanwhile, AstraZeneca faces challenges in its obesity drug pipeline, prompting industry-wide reflections on the future of weight loss therapies.
Daniel ChoMay 1, 2026
Regulatory & PolicyThe appeal by HHS against the court’s decision marks a significant development in the debate over vaccine policy alterations introduced under Kennedy’s leadership. The case highlights legal, regulatory, and public health implications that may shape future vaccine governance in the United States.
Daniel ChoApr 30, 2026